Source:http://linkedlifedata.com/resource/pubmed/id/14532971
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2003-10-8
|
| pubmed:abstractText |
Although gastric cancer with cyclooxygenase (COX)-2 overexpression is associated with poor prognosis, the mechanistic pathway remains unknown. We examined the associations between expressions of COX-2 and vascular endothelial growth factor (VEGF) in both gastric cancer cells and in human gastric cancer. The gastric cell line, Kato III, was transiently transfected with cox-2 expressing vector. The levels of COX-2, prostaglandin (PG) E2 and VEGF expression were measured post-transfection. Additionally, expressions of COX-2 and VEGF in human gastric cancer were determined by immunohistochemistry in archive gastrectomy specimens. Tumor angiogenesis was assessed by the microvessel density (MVD), which was determined by anti-CD34 immunostaining. Transient transfection of Kato III with cox-2 was associated with increased COX-2 expression, higher PGE2 production and upregulated VEGF expressions. Treatment with NS398, a specific COX-2 inhibitor, reduced VEGF expression in COX-2 expressing Kato III cells by 25%. Among the 67 gastric cancers examined, COX-2 overexpression was found in 45 (67%) cases whereas increased VEGF expression was detected in 46 (69%) cases. There was a significant association between COX-2 and VEGF expressions in gastric cancer (r=0.25, p=0.041). Additionally, tumor MVD was associated with both COX-2 (r=0.32, p=0.008) and VEGF (r=0.39, p=0.001) expressions. Our results showed that overexpression of COX-2 in both gastric cells and primary gastric cancer is associated with upregulation of VEGF and angiogenesis. Future studies should evaluate the potential anti-angiogenic effect of COX-2 inhibitors on human gastric cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1019-6439
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1317-22
|
| pubmed:dateRevised |
2006-5-1
|
| pubmed:meshHeading |
pubmed-meshheading:14532971-Aged,
pubmed-meshheading:14532971-Antigens, CD34,
pubmed-meshheading:14532971-Blotting, Western,
pubmed-meshheading:14532971-Carcinoma,
pubmed-meshheading:14532971-Cell Line, Tumor,
pubmed-meshheading:14532971-Cyclooxygenase 2,
pubmed-meshheading:14532971-Dinoprostone,
pubmed-meshheading:14532971-Female,
pubmed-meshheading:14532971-Genetic Vectors,
pubmed-meshheading:14532971-Humans,
pubmed-meshheading:14532971-Immunoblotting,
pubmed-meshheading:14532971-Immunohistochemistry,
pubmed-meshheading:14532971-Isoenzymes,
pubmed-meshheading:14532971-Male,
pubmed-meshheading:14532971-Membrane Proteins,
pubmed-meshheading:14532971-Microcirculation,
pubmed-meshheading:14532971-Middle Aged,
pubmed-meshheading:14532971-Neovascularization, Pathologic,
pubmed-meshheading:14532971-Plasmids,
pubmed-meshheading:14532971-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:14532971-Stomach Neoplasms,
pubmed-meshheading:14532971-Transfection,
pubmed-meshheading:14532971-Up-Regulation,
pubmed-meshheading:14532971-Vascular Endothelial Growth Factor A
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
|
| pubmed:affiliation |
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. wkleung@cuhk.edu.hk
|
| pubmed:publicationType |
Journal Article
|